Cargando…

Repurposing ibrutinib: therapeutic effects and implications for translational approaches in Alzheimer’s disease

Detalles Bibliográficos
Autores principales:	Lee, Hyun-ju, Hoe, Hyang-Sook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328294/ https://www.ncbi.nlm.nih.gov/pubmed/37056133 http://dx.doi.org/10.4103/1673-5374.369108

Ejemplares similares

Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study
por: Desai, Rishi J., et al.
Publicado: (2020)

Repurposing verapamil for prevention of cognitive decline in sporadic Alzheimer's disease
por: Ahmed, Heba A., et al.
Publicado: (2021)

Ibrutinib modulates Aβ/tau pathology, neuroinflammation, and cognitive function in mouse models of Alzheimer's disease
por: Lee, Hyun‐ju, et al.
Publicado: (2021)

Neurovascular ageing: transcriptomic readout and implications on therapeutic targeting in Alzheimer's disease
por: Li, Zhongqi, et al.
Publicado: (2021)

Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis
por: Huang, Fangmin, et al.
Publicado: (2023)

Estrogens still represent an attractive therapeutic approach for Alzheimer’s disease
por: Tamagno, Elena, et al.
Publicado: (2021)

Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?
por: Lord, Simon R., et al.
Publicado: (2023)

Verapamil, a possible repurposed therapeutic candidate for stroke under hyperglycemia
por: Ismael, Saifudeen, et al.
Publicado: (2022)

Translational animal models for Alzheimer's disease: An Alzheimer's Association Business Consortium Think Tank
por: Vitek, Michael P., et al.
Publicado: (2021)

Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice
por: Nam, Hye Yeon, et al.
Publicado: (2018)

Next generation therapeutics for Alzheimer's disease
por: Bredesen, Dale E, et al.
Publicado: (2013)

Emerging small-molecule therapeutic approaches for Alzheimer's disease and Parkinson's disease based on targeting microRNAs
por: Abdelrahman, Somaya A., et al.
Publicado: (2021)

Drug repurposing: Ibrutinib exhibits immunosuppressive potential in organ transplantation
por: Zhang, Qing, et al.
Publicado: (2018)

Ibrutinib repurposing: from B-cell malignancies to solid tumors
por: Massó-Vallés, Daniel, et al.
Publicado: (2016)

Antifungal Drug Repurposing
por: Kim, Jong H., et al.
Publicado: (2020)

Modeling Alzheimer’s disease: considerations for a better translational and replicable mouse model
por: Cho, Joshua D., et al.
Publicado: (2022)

Repurposing Statins for Renal Protection: Is It a Class Effect?
por: McWilliam, Stephen J., et al.
Publicado: (2017)

Unraveling the Gordian knot: genetics and the troubled road to effective therapeutics for Alzheimer’s disease
por: Restifo, Linda L
Publicado: (2021)

New Approaches to Treating Alzheimer’s Disease
por: Zheng, Hailin, et al.
Publicado: (2015)

Therapeutic Targeting of Repurposed Anticancer Drugs in Alzheimer’s Disease: Using the Multiomics Approach
por: Advani, Dia, et al.
Publicado: (2021)

Active immunotherapy and alternative therapeutic modalities for Alzheimer's disease
por: Weninger, Stacie, et al.
Publicado: (2020)

Cannabinoid pharmacology and its therapeutic uses in Alzheimer’s disease
por: Monteiro, Kadja Luana Chagas, et al.
Publicado: (2020)

TREM2 as an evolving therapeutic target in Alzheimer’s disease
por: George, Jacob
Publicado: (2023)

Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2
por: Lisi, Lucia, et al.
Publicado: (2020)

Bridging the rodent to human translational gap: Marmosets as model systems for the study of Alzheimer's disease
por: Sukoff Rizzo, Stacey J., et al.
Publicado: (2023)

Implication of salivary lactoferrin and periodontal-mediated infections in Alzheimer’s disease
por: Municio, Cristina, et al.
Publicado: (2023)

On the horizon—the value and promise of the global pipeline of Alzheimer's disease therapeutics
por: Cole, Michael A., et al.
Publicado: (2020)

Diagnostic and therapeutic potential of exosomal miRNAs in Alzheimer’s disease
por: Manna, Ida, et al.
Publicado: (2021)

Potential contributions of trace amines in Alzheimer’s disease and therapeutic prospects
por: Dhakal, Sudip, et al.
Publicado: (2020)

Repurposing cancer drugs to treat neurological diseases – Src inhibitors as examples
por: Liu, Da Zhi
Publicado: (2017)

Shifting balance from neurodegeneration to regeneration of the brain: a novel therapeutic approach to Alzheimer's disease and related neurodegenerative conditions
por: Iqbal, Khalid, et al.
Publicado: (2014)

Drug repurposing for neuroregeneration in multiple sclerosis
por: Küry, Patrick, et al.
Publicado: (2018)

Multiple sclerosis drug repurposing for neuroregeneration
por: Göttle, Peter, et al.
Publicado: (2023)

Repurposing niclosamide for the treatment of neurological disorders
por: Apolloni, Savina, et al.
Publicado: (2023)

A Multi-Objective Approach for Anti-Osteosarcoma Cancer Agents Discovery through Drug Repurposing
por: Cabrera-Andrade, Alejandro, et al.
Publicado: (2020)

Inhibition of CXCR4/CXCL12 signaling: a translational perspective for Alzheimer’s disease treatment
por: Gavriel, Yuval, et al.
Publicado: (2021)

Translation stalling and ribosome collision leading to proteostasis failure: implications for neurodegenerative diseases
por: Lu, Bingwei
Publicado: (2022)

Translational Research in Oncology: Implications for Palliative Care
por: Ghoshal, Arunangshu
Publicado: (2017)

TDP-43 and amyloid precursor protein processing: implications for Alzheimer’s disease
por: Hicks, David A.
Publicado: (2020)

Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society
por: Erickson, Claire M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1o0cf1h974b0hv1p3b8nnscakp